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Abstract
Hopes to identify genetic susceptibility loci accounting for the heritability seen 
in unipolar depression have not been fully realized. Family history remains the 
gold standard for both risk stratification and prognosis in complex phenotypes 
such as depression. Meanwhile, the physiological mechanisms underlying life-
event  triggers  for  depression  remain  opaque.  Epigenetics,  comprising 
heritable changes in gene expression other than alterations of the nucleotide 
sequence, may offer a way to deepen our understanding of the aetiology and 
pathophysiology of unipolar depression and optimise treatments. A heuristic 
target  for  exploring  the  relevance  of  epigenetic  changes  in  unipolar 
depression  is  the  hypothalamic-pituitary-adrenal  (HPA)  axis.  The 
glucocorticoid receptor (GR) gene (NR3C1) has been found to be susceptible 
to  epigenetic  modification,  specifically  DNA  methylation,  in  the  context  of 
environmental stress such as early life trauma, which is an established risk for 
depression later in life. In this review we discuss the progress that has been 
made by studies that have investigated the relationship between depression, 
early trauma, the HPA axis and the NR3C1 gene. Difficulties with the design 
of these studies are also explored. Future efforts will need to comprehensively 
address epigenetic natural histories at the population, tissue, cell and gene 
level.  The  complex  interactions  between  the  epigenome,  genome  and 
environment, as well as ongoing nosological difficulties, also pose significant 
challenges. The work that has been done so far is nevertheless encouraging 
and suggests potential mechanistic and biomarker roles for differential DNA 
methylation patterns in NR3C1 as well as novel therapeutic targets.
Introduction
The scale of present day psychiatric illness is well documented. It is thought 
to account for nearly 23% of the disease burden in the UK (Fineberg  et al., 
2013) and is similarly prominent in worldwide estimates (Murray et al., 2012). 
One  of  the  largest  diagnostic  contributors  to  this  burden  is  unipolar 
depression, which has a global lifetime prevalence rate of up to 17% (Flint 
and Kendler, 2014). Unipolar depression is projected to become the greatest 
worldwide cause of disability-adjusted life years (DALYs) by the year 2030 
(WHO, 2008) and is already associated with significant mortality (Antypa  et 
al.,  2013).  Thus,  there  remains  an  ever-growing  need  to  further  our 
understanding of depression in order to optimise treatments and to alleviate 
suffering (Collins  et al.,  2011).  Deterministic genetic models for psychiatric 
illness have proved elusive. Genome-wide association studies (GWAS) have 
not  translated  into  significant  therapeutic  gains  for  disorders  such  as 
depression and aetiology from a genetic viewpoint remains opaque (Lewis et 
al.,  2010;  Ripke  et  al.,  2013).  Possible  reasons  for  this  include  well-cited 
nosological difficulties (Casey  et al., 2013) incorporating phenomenological, 
psychopathological and pathophysiological heterogeneity, small effect sizes of 
individual  genes  and  overestimated  heritability  (McGuffin  et  al.,  2007; 
Bohacek  and  Mansuy,  2013;  Uher,  2014).  However,  a  growing  body  of 
evidence  suggests  that  epigenetic  modification  could  be  a  biologically 
significant  factor  in  depression  with  potential  diagnostic,  prognostic  and 
therapeutic uses (Massart et al., 2012; Bohacek et al., 2013; Sun et al., 2013; 
Bagot et al., 2014).
Heritability of depression
For many years twin and family studies have highlighted the importance of 
genetic  and  environmental  factors  in  the  mediation  of  the  vulnerability  to 
depression  (Cohen-Woods  et  al.,  2013).  In  the  first  meta-analysis  of 
epidemiological  studies  in  depression,  Sullivan  et  al. (2000)  compared 
susceptibility in monozygotic and dizygotic twins. The majority of the variance 
in  liability  was attributed to  environmental  effects  specific  to  the individual 
(63%), whilst  genetic effects accounted for 37%. Subsequent studies have 
produced similar results (Kendler et al., 2006; Franz et al., 2011; Nivard et al., 
2014).  This  genetic  contribution  has  been  examined  using  linkage  and 
association studies. Gene linkage studies for depression, as well as for other 
common complex  disorders,  have  been  perceived  by  some to  be  of  only 
limited success (McGuffin  et al.,  2007; Nair and Howard,  2013) hence the 
focus on GWAS. However, even for simple traits, genetic variants identified by 
GWAS are  rarely  shown  to  account  for  more  than 20% of  the  heritability 
(Wood et al., 2014). GWAS has had limited success for depression in finding 
significant associations with individual genetic variations and there has been 
no evidence for a recessive model (Cohen-Woods et al., 2013; Chang et al., 
2014;  Flint  and Kendler,  2014;  Levinson  et  al.,  2014;  Power  et  al.,  2014; 
Schneider et al., 2014). Even when technical and statistical aspects of GWAS 
have been taken into account (Gusev et al., 2013) the extent of this disparity 
between  expected  and  verified  genetic  components  in  depression  has 
remained considerable  (Castillo-Fernandez  et  al.,  2014)  and family  history 
continues to be the most effective method of predicting risk (Maher, 2008). 
Nevertheless,  trying  to  dovetail  epidemiological  studies  which  suggest  a 
considerable genetic component for depression with genetic studies providing 
a  dearth  of  single  nucleotide  polymorphism (SNP)  associations  remains  a 
significant problem. 
The HPA axis 
One major endocrinological finding in depression is of a dysregulation of the 
HPA axis – a pathway important in regulating stress responsivity. Stress has 
profound  effects  upon  a  broad  range  of  physiological  systems  and  is  an 
established trigger for mental illness (Meaney, 2001; Gallagher  et al., 2007; 
Binder et al., 2008; Turner et al., 2010; Klengel et al., 2014). The HPA axis is 
the foremost neuroendocrine stress response system. Dysregulation of the 
HPA axis  in  unipolar  depression  has been consistently  reported  since the 
1960s (Gibbons, 1964; O’Toole et al., 1997; McAllister-Williams et al., 1998; 
Holsboer,  2000;  Young,  2004;  Moser  et  al.,  2007;  Pariante and Lightman, 
2008). Neuroendocrine studies have shown increased basal and/or activated 
levels of the HPA axis hormones – corticotropin-releasing hormone (CRH), 
vasopressin  (AVP),  adrenocorticotropic  hormone (ACTH)  and  cortisol  –  in 
plasma, saliva and cerebrospinal fluid (CSF) (Herbert, 2013; Belvederi Murri 
et al.,  2014). Structural changes have also been seen in post-mortem and 
imaging studies of depressed patients including  increased numbers of CRH 
secreting  neurones  in  the  hypothalamus  (Raadsheer et  al.,  1994)  and 
enlarged  pituitary  and  adrenal  gland  volumes  (Kessing  et  al.,  2011). 
Meanwhile  non-suppression  in  the  dexamethasone/  CRH  test  has  been 
associated with  inferior  treatment response and increased relapse rates in 
depression (Aubry et al., 2007; Ising et al., 2007; Medina et al., 2013).
The  HPA  axis  is  regulated  by  negative  feedback  loops  incorporating 
glucocorticoids  (GC)  and glucocorticoid  receptors  (GR)  (Alt  et  al.,  2010). 
Thus, studies exploring the mechanism underlying the HPA axis dysregulation 
that has been documented in depression have focused upon abnormal GR 
expression and function (Pariante, 2006 and 2009; Cowen, 2009; Anacker et 
al.,  2011).  Indeed  preclinical  and  clinical  investigations  have  implicated  a 
significant  role  for  GR abnormalities  in  depression.  Using  knock-out  mice 
Boyle  et al. (2005) demonstrated that reduced GR function led to disrupted 
negative feedback inhibition of the HPA axis and depression-like behaviour. 
Depressed patients have shown reduced peripheral GR levels and increased 
24-hour cortisol levels (Yehuda et al., 1993). In line with this, decreased GR 
mRNA  has  been  demonstrated  in  post-mortem  frontal  cortices  from 
depressed patients (Webster et al., 2002), although a more recent study has 
found  increased  GR  expression  in  amygdala  samples  from  depressed 
patients (Wang et al., 2014). These findings have been bolstered by studies 
implicating  improved  GR  function  and  increased  GR  expression  in  the 
mechanism of action of certain antidepressants (Pariante and Miller, 2001). 
Early life adversity, depression and the HPA 
axis
The impact of maternal care and early life adversity has been investigated 
across several species. Rodents temporarily separated from their mothers in 
the first few months of life, and those whose mothers provide low levels of 
licking and grooming (LG)  and arched back nursing  (ABN)  care  (Meaney, 
2001; Daskalakis  et al.,  2013), have been shown to exhibit  depression-like 
phenotypes (Caldji  et al., 2000; Murgatroyd et al., 2009). Early adversity has 
also  been associated with  abnormal  HPA axis  function  (Fish  et  al.,  2004; 
Archer  et  al.,  2014).  Liu  et  al. (1997)  demonstrated  that  high  LG-ABN 
maternal conditions, triggered by brief human handling, were associated with 
lower  levels  of  plasma  adrenocorticotrophic  hormone  (ACTH)  and 
corticosterone (CS) in response to stress in rat offspring up to 100 days old. 
These  offspring  also  had  greater  GC  sensitivity,  increased  levels  of 
hippocampal GR mRNA and lower levels of hypothalamic CRH mRNA. In an 
associated study, Francis  et al. (1999) showed that rat pups cross-fostered 
from low to high LG-ABN mothers had dampened behavioural responses to 
stress.  More  interesting  still,  these  offspring  emulated  their  high  LG-ABN 
foster mothers when caring for their own offspring, while low LG-ABN foster 
mothers  rearing  pups  from  high  LG-ABN  biological  mothers  produced 
offspring  with  heightened  stress  responses  and  low  LG-ABN  maternal 
behaviour.  Further studies by Murgatroyd and Nephew (2013, and another 
study  currently  in  submission)  have  been  able  to  show that  exposing  rat 
mothers to chronic stress during lactation leads to reduced levels of maternal  
care  as  well  as  altered  neuropeptide  regulation  and  GR  expression. 
Moreover,  pups  whose  mothers  were  exposed  to  chronic  stress  tend 
themselves  to  exhibit  reduced  maternal  care  in  adulthood.  These  results 
supported  prior  studies  (Denenberg and Rosenberg,  1967;  Danchin  et  al., 
2011)  demonstrating that  differences in  gene expression  could be passed 
from one generation to the next by non-genomic means. Further work has 
been carried out on epigenetic transgenerational inheritance and it continues 
to attract much attention (Bohacek et al., 2013; Crean et al., 2014; Babenko 
et al., 2015). 
In humans early life adversity is acknowledged as a significant risk factor for  
many psychiatric and non-psychiatric illnesses (Rutter, 1985; Meaney, 2001; 
Maniglio, 2009).  Childhood maltreatment – incorporating physical, emotional 
and sexual abuse and physical and emotional neglect – is a significant source 
of early life adversity in human populations. In Britain, childhood maltreatment 
has been estimated to occur in 15-25% of the population  (May-Chahal and 
Cawson,  2005;  Radford  et  al.,  2013)  with  comparable  figures  quoted 
internationally (Ishida et al., 2013; Barbosa et al., 2014; Finkelhor et al., 2014; 
Wildeman et al., 2014).  Those who are subjected to childhood maltreatment 
are thought to be at greater risk of later life depression (Klengel et al., 2014). 
More  specifically,  Bifulco  et  al. (1991)  demonstrated  an  increased  risk  of 
depression  in  women  who  had  been  abused  as  children  and  other 
subsequent  studies  have  supported  these  findings  (Kendler  et  al.,  2000; 
Widom et al., 2007; Alt et al., 2010; Bale et al., 2010; Heim et al., 2010). Such 
individuals  can  exhibit  persistent  neuroendocrine  and  anatomical  changes 
including: glucocorticoid insensitivity, increased central CRH activity, immune 
upregulation and reduced hippocampal volume (Heim and Nemeroff,  2001; 
Heim et al., 2008; Hornung and Heim, 2014). Similar abnormalities have been 
seen in parentally bereaved children in the form of elevated 24-hour salivary 
cortisol  concentrations  (Nicolson,  2004)  and  elevated  cortisol  in  the 
dexamethasone/  CRH test  (Tyrka  et  al.,  2008).  However,  stress  diathesis 
remains a complex phenomenon with no absolute demarcation between brief 
(potentially beneficial) and persistent (potentially damaging) stress. In some 
instances early  adversity  has appeared to  prime,  or  ‘stress  inoculate’,  the 
individual  to  later  adversity  (Anisman  et  al.,  1998;  Carpenter  et  al.,  2007; 
Watson  et al., 2007; Elzinga  et al., 2008; Daskalakis  et al., 2013). Thus, a 
relationship clearly exists between early adversity, depression and HPA axis 
function. The potential for individual genes to exert a mediating role in this 
relationship is the subject of much current study. One such gene is NR3C1. 
The NR3C1 gene 
NR3C1 is found on chromosome 5q31-32 and is over 150kb in length (Franke 
and Foellmer, 1989; Turner et al., 2014). It has 8 translated exons (numbered 
2 to 9) and is thought to have up to fourteen untranslated alternative first  
exons (termed 1a through to 1j, with 1a and 1c having six further sub-divisions 
between them) at its 5’ end (Daskalakis and Yehuda, 2014).  NR3C1 has a 
complex promoter structure with one promoter for each of its single alternative 
first exons (Turner et al., 2010). Alternative first exon transcripts are thought 
to be important for adjusting GR levels in accordance with cell or tissue type 
and dynamic environmental conditions (Turner  et al., 2006) by differentially 
regulating  translation  efficiency and RNA stability  (Bockmühl  et  al., 2011). 
Transcription  factors  known  to  modulate  alternative  first  exon  use  include 
nerve growth factor inducible protein A (NGFIA) which binds to the exon 1f 
promoter (Weaver  et al., 2004).  GR is a ligand-activated transcription factor 
crucial  for  the effective  functioning of  the  HPA axis.  It  translocates to  the 
nucleus  after binding  GC to  regulate  the  activity  of  specific  target  genes, 
including  NR3C1 itself.  NR3C1 splice  variants  and  mRNA  levels,  GR 
isoforms,  co-activators  and  co-repressors  have  all  been  associated  with 
variations in GR activity (Binder,  2009; Turner  et al.,  2010; Anacker et al., 
2011; Szczepankiewicz et al., 2014). Although GR is ubiquitously expressed, 
its levels are thought to be tightly controlled according to tissue, or even cell, 
type. Thus, within the brain, levels are higher in areas involved in the stress 
response  such  as  the  paraventricular  nucleus,  hippocampus  and  anterior 
pituitary (Karanth et al., 1997; Uchida et al., 2008; Booij et al., 2013). 
Epigenetics
Epigenetic  mechanisms  -  encompassing  DNA  methylation,  histone 
modification and non-coding RNAs - act to modulate gene expression (Bird, 
2002; Bird, 2007; Weaver et al., 2007; Akbarian and Huang, 2009; Bale et al., 
2010; Murgatroyd and Spengler, 2011; Booij et al,, 2013) and arguably have 
the  potential  to  explain  the  extent  and  nature  of  the  risk  of  depression 
conferred  by  the  interaction  between  environmental  and  genetic  factors. 
Factors  determining  the  extent  of  the  epigenetic  modifications  include cell 
type,  developmental  stage  and  the  nature  and  severity  of  environmental 
stressors. 
DNA methylation,  the most widely studied epigenetic modification, involves 
the addition of a methyl group to the 5-carbon position of a cytosine at the 5’  
end of  cytosine-guanine dinucleotides (CpG sites).  CpG clusters (‘islands’) 
are often present within gene promoter regions in an unmethylated state but 
when they become methylated the gene with which they are associated is 
usually silenced. Methylation is thought to exert this silencing effect, in concert 
with other epigenetic modifications and signalling pathways (Day and Sweatt, 
2011; Reul, 2014), by inhibiting the binding of transcription factors to promoter 
regions. Gene promoter regions, as well as the main gene bodies themselves, 
have  commonly  been  investigated  for  differential  methylation  patterns  but 
more  recently  methylation  within  enhancer  elements has  also  been 
recognised (Plank and Dean, 2014). The impact of the location and the extent 
of methylation required to prevent gene expression remains unclear but, in 
cancer studies using discordant monozygotic twins, large effects have been 
seen with absolute increases in methylation of 10% or less (Galetzka et al., 
2012; Heyn  et al.,  2013). DNA methylation, acknowledged as an important 
factor in tissue development for many years (Holliday and Pugh, 1975; Riggs, 
1975;  Razin  and  Riggs  1980),  has  emerged  as  a  potential  underlying 
mechanism for changes in GR expression. 
Figure 1: 
To be inserted here.
Early life adversity and methylation of NR3C1 in 
animals
In 2004 Weaver et al. demonstrated that in rat pups of low LG-ABN mothers 
NR3C1 methylation was increased in hippocampal samples (to rates of 80-
100%) within the NGFIA binding site of the GR gene’s exon 1(7) promoter, the 
homologue of exon 1f in humans, and that this was associated with reduced 
GR expression.  Conversely  they showed that  high LG-ABN maternal  care 
was associated with  lower methylation rates (0-10%) of the exon 1(7) GR 
promoter in offspring. In agreement with a prior study (Meaney et al., 1996) 
examining GR expression these differences in methylation rates persisted into 
the offspring’s adulthood. Group differences were eliminated by trichostatin A, 
a histone deacetylase inhibitor thought to promote demethylation (Ou  et al., 
2007), as well as by cross-fostering. This was the first study in the literature to 
show a clear link between mothering, long-term changes in DNA methylation 
patterns and subsequent gene expression. Further studies were conducted 
with,  at  times,  conflicting  results.  Daniels  et  al. (2009),  for  instance, 
investigated the impact of separating rat  pups from their  mothers between 
postnatal  day  2  and  14.  Assessment  of  hippocampi  at  postnatal  day  21 
revealed no significant change in methylation within exon 1(7) or the NGFIA 
binding  site  between  pups  separated  from their  mothers  and  pups  raised 
normally. Nevertheless, Weaver et al. (2007) demonstrated that high LG-ABN 
care was  associated with  demethylation  of  the  5’  CpG dinucleotide  in  the 
NGFIA response element specifically. Additionally,  the authors showed that 
increased  LG-ABN was  correlated  with  greater  NGFIA  binding,  histone 
acetylation, GR mRNA levels, hippocampal NGFIA expression and increased 
amounts of GR protein. 
Early life adversity and methylation of NR3C1 in 
humans
One  of  the  first  studies  in  humans  to  examine  the  relationship  between 
prenatal adversity and  NR3C1 methylation was by Oberlander  et al. (2008). 
Children of  depressed mothers  who had received medication (n=33)  were 
compared with children of untreated depressed mothers (n=13) and controls 
(n=36). An association was seen between prenatal exposure to third trimester 
maternal depression and increased methylation levels of the NGFIA binding 
site in exon 1f of the  NR3C1 promoter (deemed CpG sites 1 to 3) at birth. 
CpG site 3, within the NGFIA binding site, was also associated with increased 
cortisol response at 3 months of age.  Antidepressant medication had been 
associated with increased GR mRNA levels in rodents (Pepin  et al.,  1992; 
Pariante  and Miller,  2001; Yau  et  al.,  2002)  and increased GR density  in 
human  peripheral  blood  cells  (Calfa  et  al.,  2002),  whilst  NR3C1 
polymorphisms  have  been  observed  to  predict  antidepressant  medication 
responses (Binder  et al.,  2004; Spijker and van Rossum, 2012).  However, 
maternal treatment with selective serotonin reuptake inhibitors (SSRIs) in the 
Oberlander et al. study did not have any observable effect on offspring CpG 
methylation  status.  Nevertheless,  these  findings  encouraged  other  studies 
(Hompes et al. 2013 for example) to assess the same portion of the exon 1f 
promoter and CpG sites. Conradt et al. (2013) reported that newborn offspring 
exposed to maternal  depression  in  utero had increased methylation at the 
authors’  CpG  site  2  within  exon  1f  as  well  as  adverse  neurobehavioural 
outcomes. 
Radtke  et  al. (2011)  examined  DNA  methylation  using  peripheral  blood 
samples taken from children (n=24) aged up to 19 years old whose mothers 
had  been  exposed  to  violence  before,  during  and  after  their  pregnancy.  
Increased  methylation  rates  in  children  were  significantly  associated  with 
maternal exposure to violence during their pregnancy. Methylation was seen 
in 7 of the 24 children, in 5 of the 10 CpG sites examined and at rates of up to 
10%. Strikingly, there was no association between child  NR3C1 methylation 
and maternal exposure to violence either before or after pregnancy. Maternal 
NR3C1 methylation was not significantly correlated with methylation levels in 
their children and was unaffected by exposure to violence. This study was the 
first in humans to show an apparently sustained dysregulation of the HPA axis 
associated with previous early life psychological stress. However, the lack of 
data over such a long periods of time, up to 19 years in some instances, and 
the small sample sizes used meant that innumerable confounders could not 
be ruled out and the statistical power of the study remained relatively limited.  
Such site-specific findings, again using the portion of the exon 1f adopted by 
Oberlander et al. (2008), were seen in a study by Tyrka et al. (2012) in which 
99 healthy adult subjects showed correlations between NR3C1 methylation at 
CpG  sites  1  and  3  in  the  exon  1f  promoter  and  previous  childhood 
maltreatment, parental care and parental loss. However, methylation rates at 
these sites and cortisol response were not correlated and the study did not 
incorporate gene expression data. Hence, the functional significance of their 
findings remained debatable. 
Depression and methylation of NR3C1 
In a study using buccal DNA from healthy individuals (n=92) Edelman et al. 
(2012)  were  able  to  show that  methylation  at  a  single  CpG site  within  a 
binding  site  for  NGFIA  correlated  with  cortisol  response  to  stress. 
Furthermore, as a result of epigenetic modifications being chemically stable 
yet  modifiable  in  accordance with  dynamic  environmental  factors  (Meaney 
and  Szyf,  2005; Sweatt,  2009)  NR3C1 methylation  has  been  afforded 
considerable  explanatory  potential  in  trying  to  understand  both  HPA  axis 
dysregulation and depression  (Turner  et al., 2010). Inconsistent  results from 
NR3C1 SNP studies in depression (Bouma  et al., 2011; Lahti  et al., 2011; 
Lewis  et al., 2011; Engineer  et al., 2013; Galecka et al., 2013; Koper  et al., 
2014) have added further impetus to this field of enquiry.
In  2010  Alt  et  al. conducted  a  study  exploring  the  possible  association 
between  methylation  of  NR3C1 and  depression.  The  authors assessed 
NR3C1 methylation in post-mortem samples from depressed patients (n=6) in 
multiple limbic brain regions compared to controls (n=6). Hippocampal exon 1f 
transcripts  were  reduced  in  depressed  patients  and  NGFIA  was  down-
regulated within the hippocampus, cingulate gyrus and nucleus accumbens. 
However, these data demonstrated very low overall levels of methylation in 
both depressed and control brains, whilst the  NR3C1 promoter for exon 1f 
was  completely  unmethylated  in  all  of  the  samples  taken.  Thus,  the 
mechanism  for  this  down-regulation  in  depressed  brains  appeared  to  be 
entirely  independent  of  methylation  patterns.  However,  as  the  authors 
themselves acknowledged, this study’s  power was limited by small  sample 
sizes. More recently Na et al. (2014) compared methylation levels of NR3C1’s 
promoter  region  in  depressed  patients  (n=45)  and  controls  (n=72).  The 
authors  found  hypomethylation,  rather  than  hypermethylation,  at  two  CpG 
sites in patients. Neither the Alt et al. (2010) nor the Na et al. (2014) studies 
were  able  to  provide  definitive  data  regarding  HPA  axis  functioning  or 
childhood  trauma.  This  would  appear  to  be  crucial,  as  illustrated  by  the 
following studies incorporating early adversity into models of depression, HPA 
axis dysfunction and methylation of NR3C1 at different life stages.
Early life adversity, depression and methylation of 
NR3C1
McGowan  et al. (2009) compared methylation rates in hippocampi of post-
mortem samples from suicide victims, with and without histories of childhood 
abuse, and controls (n=12 for each of these three groups). Two thirds of the 
suicide victims, whether abused or not, were retrospectively diagnosed with 
mood disorders via psychological autopsies (DSM-III-R). Levels of childhood 
abuse in suicide victims correlated with higher levels of  methylation of the 
NR3C1 promoter as well as lower NR3C1 mRNA levels, both overall and for 
the  exon  1f  splice  variant  alone.  There  was  no  significant  difference  in 
methylation rates of the exon 1f  NR3C1 promoter or  NR3C1 mRNA levels 
between non-abused suicide victims and controls. In abused suicide victims 
CpG  site-specific  increases  in  methylation  were  associated  with  reduced 
NGFIA binding  and NGFIA-induced transcription.  However,  this  study was 
limited statistically by the small  sample sizes used for each group and the 
removal of outliers in their final analysis. Also of note was that McGowan et 
al. (2009) reported exon 1f levels accounting for up to 60% of the total amount 
of expressed NR3C1 promoters. Alt et al. (2010), meanwhile, gave a figure in 
accordance with previous studies of less than 1%. Such relatively low levels 
of exon 1f could detract from its apparent functional importance in comparison 
to other alternative first exons. Whilst dramatically different expression rates 
between studies may also reduce the confidence with which results can be 
generalized. 
Perroud et al. (2011) investigated the correlation of the severity of childhood 
maltreatment with  methylation  rates in  NR3C1 for  patients diagnosed with 
borderline  personality  disorder  (BPD)  (n=101),  depression  (n=99)  or 
depression with co-morbid post-traumatic stress disorder (n=15). A portion of 
the exon 1f promoter was analysed with reference to the sequence used by 
Oberlander et  al. (2008).  They  were  able  to  show  highly  significant 
associations between methylation of NR3C1 and the severity and number of 
sexual abuse episodes. In a study by Melas et al. (2013) salivary DNA from 
depressed adults (n=92) were compared with controls (n=82). They examined 
whether differential methylation rates of NR3C1 were associated with various 
adversities experienced in childhood. Of the 47 CpG sites spanning the exon 
1f promoter that were analysed increased methylation was seen at a single 
CpG site, near to the NGFIA binding region. This was significantly associated 
with  early  parental  death.  However,  this  study  did  not  assess  childhood 
abuse, the numbers involved in the adversity sub-groups were not large and 
only females were included. 
Very few studies have identified candidates for human maternal behaviours 
equivalent to rat LG-ABN. However, in rats the effects of licking and grooming 
have been shown to be mimicked by stroking pups with a brush (Mulligan et 
al., 2012). A study by Sharp  et al. (2012) demonstrated moderation of the 
effects  of  prenatal  maternal  depression  upon  emotional  and  physiological 
outcomes in human infants through mothers stroking their babies in their first 
weeks of life. A very recent follow-up study by Murgatroyd  et al. (2015) has 
showed  reduced  NR3C1 methylation  associated  with  maternal  stroking  in 
these children, hence bolstering the possible role of epigenetic mechanisms in 
the long-term effects of early life stress and maternal care. Interestingly, the 
same study  also  found  interactive  effects  between  prenatal  and  postnatal 
maternal depression on methylation of  NR3C1’s exon 1f. Infants of mothers 
with low prenatal depression showed increased methylation when exposed to 
increased  postnatal  depression  -  consistent  with  an  interplay  between 
prenatal and postnatal environments. In general terms this is supportive of the 
foetal origins hypothesis of human disease according to which environmental 
exposures in utero lead to adaptive modifications in foetal development that 
act to increase fitness in similar postnatal environments.
Table 1: 
To be inserted here.
Methodological issues and possible future studies
Whilst  these  human  studies  have  added  overall  support  to  a  role  for 
epigenetic  modification  in  the  link  between  early  adversity,  HPA  axis 
dysregulation  and  depression  vulnerability,  attention  is  increasingly  being 
drawn to  inconsistencies in  study design  that  may have prevented causal 
inferences being made (Daskalakis and Yehuda, 2014; Turecki and Meaney, 
2014). In this final section an attempt will be made to give an overview of such 
inconsistencies in order to offer a potential direction for future studies. 
Unlike the majority of  animal  studies examining  NR3C1 methylation,  many 
types  of  potential  stressors,  sometimes  at  different  developmental  stages, 
have been used to represent early human adversity. For example, Oberlander 
et al. (2008) used prenatal exposure to maternal depression whilst Radtke et 
al. (2011) examined the impact of pre- and perinatal  exposure to violence 
against the mother. Both McGowan  et al. (2009) and Perroud  et al. (2011) 
used  histories  of  childhood  abuse.  Studies  examining  the  impact  of  early 
adversity in humans is clearly more limited in design by ethical considerations 
when  compared  to  animal  studies.  Given  the  relatively  complex  nature  of 
human  interactions  and  stress  diathesis  there  is  a  need  to  minimise 
confounders  by  standardising  the  assessment  of  stressors  whenever 
possible. With regards to using stressors at different developmental stages, 
the natural history of site-specific methylation, such as the exon 1f promoter of 
NR3C1,  in  individual  subjects  has  not  been  explored.  Prenatal  stress 
exposure, as used by Oberlander et al. (2008) and Radtke et al. (2011), has 
helped  to  establish  the  temporal  boundaries  of  what  appears  to  be  a 
developmentally  sensitive  period  for  a  possible  causal  chain  of  adversity,  
epigenetic  modification,  HPA  dysregulation  and  subsequent  depression. 
However, substantial differences can be expected in the nature of stresses 
prenatally  compared  to  postnatally,  as  well  as  their  developmental 
consequences,  and  this  again  risks  introducing  many  confounders  when 
attempting to interpret data. Future studies need to comprehensively detail 
adverse events, as is common practice on psychiatric inpatient wards and to a 
lesser degree in the community setting, over extensive periods of time and to 
combine this with regular assessments of epigenetic modifications.    
Human studies  have also  undertaken analysis  in  different  types  of  tissue. 
Peripheral blood has often been used due to its relative acceptability from the 
patient’s  perspective  and  its  clinical  practicality.  Radtke  et  al. (2011)  and 
Perroud et al. (2011) used DNA extracted from peripheral whole blood whilst 
Oberlander et al. (2008) investigated mononuclear cells from the cord blood of 
newborns. Other studies have looked at post-mortem tissue: McGowan et al. 
(2009)  analysed  hippocampal  specimens whilst  Alt  et  al. (2010)  looked at 
several different limbic regions. Melas  et al. (2013), meanwhile,  used DNA 
from saliva. It has already been highlighted that methylation levels may differ 
between cell types (Glossop  et al., 2013; Simar  et al., 2014) meaning that 
comparisons between studies using entirely different tissues could be very 
challenging. However, evidence has emerged that peripheral blood may be an 
appropriate  tissue  to  identify  biomarkers  for  depression  in  the  context  of 
genetic studies (Rollins et al. 2010; Hepgul et al., 2013), whilst in a review by 
Tylee  et al. (2013) the methylome was shown to be more highly correlated 
between blood and brain samples than the transcriptome. Provencal  et al. 
(2012) showed that in rhesus macaques variations in mothering (surrogate 
versus  mother  reared)  led  to  differential  methylation  rates  including  the 
A2D681  gene which  is  the homologue of  NR3C1 in  humans.  A weak  but 
significant correlation was seen in differential methylation between prefrontal 
cortex samples and T lymphocyte cells. The use of blood samples does have 
an advantage over the use of post-mortem and placental tissue given that 
these samples  are  taken at  markedly different  physiological  states.  Saliva 
samples involve cells from different developmental lineages to both brain and 
blood  tissue  and  hence  the  validity  of  its  use  is  unclear.  These  various 
confounders  mean  that  many  more  studies  will  be  needed  before  effects 
directly attributable to early life trauma can be separated from those relating to 
tissue type.  Future investigations also need to  involve  repeated peripheral 
samples taken from individuals who have nominated themselves for future 
brain  donation.  The  measurement  of  NR3C1 methylation  levels  across 
various  brain  regions  in  these  individuals  will  allow  the  consolidation  of 
findings from different tissue types and could lead to effective and clinically 
acceptable  therapeutic  interventions.  Additionally,  efforts  must  be  made to 
isolate specific cell types, primarily those cells found in peripheral blood, in 
order to establish cell-specific methylation profiles (El-Sayed et al., 2012).    
Of  particular  note in  the studies published to  date is  that  there has been 
considerable heterogeneity in exactly where, and to what extent, within the 
NR3C1 gene  and  its  promoter  regions,  methylation  has  been  assessed 
(Labonte et al., 2012; Daskalakis and Yehuda, 2014). Much of the work that 
has been done has involved a specific location of the  NR3C1 gene itself, 
namely  exon  1f  and  its  promoter  region  incorporating  the  binding  site  for 
NGFIA. In the first of such studies Oberlander et al. (2008) looked at thirteen 
CpGs  in  an  area  comprising  exon  1f,  its  promoter  and  a  further  section 
downstream of this, using Weaver et al’s 2004 study as their main reference. 
McGowan et al. (2009), meanwhile, looked at 39 CpGs across exon 1f and its 
promoter. Perroud et al. (2011) looked at eight CpG sites across the exon 1f 
promoter  and  a  further  downstream  region.  Finally,  Melas  et  al. (2012) 
analysed what are thought to be all of the 47 CpG sites throughout the main 
body and promoter region of NR3C1’s exon 1f. Although some effort has been 
made to correlate individual CpG sites across different studies this has not 
always been possible, and despite occasional agreement in which sites are 
differentially  methylated  no conclusive  patterns  have yet  emerged.  Hence, 
there would be benefit in researchers adopting a unified and comprehensive 
approach to the nucleotide sequence being assessed as well as the individual 
CpG sites within  it.  Given the  extensive  adoption so  far  of  the nucleotide 
sequence from the Oberlander et al. (2008) study it is recommended that this 
continues to be used as the minimum and necessary sequence coverage for 
future NR3C1 methylation studies in depressed patients with a history of early 
maltreatment. 
Investigators have examined different functional  correlates for the changes 
observed in NR3C1 methylation. For example, Oberlander et al. (2008) used 
salivary cortisol measurements in the morning, following a stressor and in the 
evening, whereas McGowan et al. (2009) assessed NR3C1 mRNA levels as 
well  as  NGFIA  binding  and  NGFIA-induced  transcription.  Once  again  this 
heterogeneity  of  approaches  has  potentially  impaired  efforts  to  establish 
causal  relationships.  Although  investigators  have  amassed  a  considerable 
amount of evidence for an association between differential methylation and 
HPA axis  function  in  humans,  a  causal  relationship  still  needs to  be  fully 
established. 
Lastly,  a recurrent issue in studies examining childhood adversity is that of 
confounding factors relating to recall bias and the participant’s current mental  
state. Ideally, long term follow-up of children up to and beyond the period of 
maximum risk of the development of psychiatric illnesses, with objective and 
detailed  documentation  of  the  reported  maltreatment,  will  minimise  this 
complication  and  simultaneously  allow  more  effective  exploration  of  the 
consequences of particular maltreatment categories.  
Summary
Studies  have  continued  to  emerge  that  implicate  hypermethylation  of 
NR3C1’s exon 1f promoter occurring following early trauma with this being 
associated  with  HPA  axis  dysfunction  and  depression. Results  have, 
however, been inconsistent at times and not without occasional controversy 
(Dyer, 2014). How much of the observed variation of findings is due to inter-
subject variability in underlying pathophysiology, as opposed to experimental 
design, remains to be seen. 
There  is  a  need  for  researchers  to  adopt  more  consistent  approaches  to 
document the natural history of methylation patterns at individual CpG sites 
within NR3C1 after early life adversity. This natural history will need to include 
other  environmental  factors  such  as  age  and  diet  (Mathers  et  al., 2010; 
Murgatroyd and Spengler, 2011; Suderman  et al., 2012; Tyrka  et al., 2012; 
Bakulski  and Fallin, 2014). A diet low in folate and high in methionine, for 
example, has already been associated with increased NR3C1 methylation in 
mice  (Sulistyoningrum  et  al.,  2012).  The  use  of  newer,  more  powerful 
technologies such as epigenome-wide association studies (EWAS) and single 
cell  analysis  are exciting but  will  bring challenges in terms of  consistency, 
defining cell type, cost and data analysis (Plessy et al., 2012; Callaway, 2014; 
Robinson et al., 2014). 
A significant challenge in the epigenetics of mental illness also continues to 
be the complex nature of these disorders and their aetiology (Caspi et al., 
2003; Eaves et al., 2003; Bowes and Jaffee, 2013; Ehlert, 2013; Brown et al., 
2014; Castillo-Fernandez et al., 2014; Kanherkar et al., 2014). As is the case 
for most research in psychiatry there is the ever-present issue of difficulties 
with  psychiatric  nosology.  Most  authorities  believe  that  the  diagnostic 
category of “major depressive disorder” contains a heterogeneous collection 
of disorders with differing underlying pathophysiologies (Schmidt et al., 2011). 
This will  clearly hamper the interpretation of epigenetic data.  This may be 
addressed  by  exploring  the  relationship  between  epigenetic  status  and 
endophenotypes such as those defined using the Research Domain Criteria 
initiative (Insel et al., 2010; Casey et al., 2013). 
Studies on depression and NR3C1 methylation are exciting in two main ways. 
Firstly  they  suggest  a  hitherto  untapped  approach  that  could  help  to 
synthesise a comprehensive and necessarily eclectic theory of depression, 
aiding our understanding of causal factors and identifying disease biomarkers. 
Secondly, they have the potential to point towards novel therapeutic targets 
since epigenetic changes are potentially reversible and therefore amenable to 
intervention,  as  has  been  seen  in  cancer,  cardiovascular  disease  and 
neurological  disorders  (Heerboth  et  al.,  2014; Sandhu  et  al.,  2015). 
Epigenetics offers a way to optimise the diagnosis, prognosis and treatment of 
depression.  In  doing  so  it  could  reduce  depression’s  global  burden whilst 
simultaneously providing a truly personalised medicine.
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